Quote this publication Share Print

ZORYON (méthadone)

Opinions on drugs - Posted on Mar 24 2020

Reason for request


Substantial clinical benefit but no demonstrated clinical added value in the treatment of chronic cancer pain not adequately relieved by other step 3 opioids

  • ZORYON has an MA in the chronic treatment of moderate to severe cancer pain in patients not adequately relieved by other step 3 opioids.
  • Methadone has been used off-label for numerous years in the treatment of patients with chronic cancer pain. Treatment with ZORYON (methadone) may be initiated in these patients during a step 3 opioid rotation.
  • The pharmacokinetic characteristics and safety data for methadone call for caution when initiating treatment; initiation should be performed in a hospital setting by a pain management or palliative care team experienced in the use of the product.

Clinical Benefit



Clinical Added Value

no clinical added value


Contact Us

Évaluation des médicaments